RT Journal Article
T1 Novel Biomarkers of Habitual Alcohol Intake and Associations With Risk of Pancreatic and Liver Cancers and Liver Disease Mortality.
A1 Loftfield, Erikka
A1 Stepien, Magdalena
A1 Viallon, Vivian
A1 Trijsburg, Laura
A1 Rothwell, Joseph A
A1 Robinot, Nivonirina
A1 Biessy, Carine
A1 Bergdahl, Ingvar A
A1 Bodén, Stina
A1 Schulze, Matthias B
A1 Bergman, Manuela
A1 Weiderpass, Elisabete
A1 Schmidt, Julie A
A1 Zamora-Ros, Raul
A1 Nøst, Therese H
A1 Sandanger, Torkjel M
A1 Sonestedt, Emily
A1 Ohlsson, Bodil
A1 Katzke, Verena
A1 Kaaks, Rudolf
A1 Ricceri, Fulvio
A1 Tjønneland, Anne
A1 Dahm, Christina C
A1 Sánchez, Maria-Jose
A1 Trichopoulou, Antonia
A1 Tumino, Rosario
A1 Chirlaque, María-Dolores
A1 Masala, Giovanna
A1 Ardanaz, Eva
A1 Vermeulen, Roel
A1 Brennan, Paul
A1 Albanes, Demetrius
A1 Weinstein, Stephanie J
A1 Scalbert, Augustin
A1 Freedman, Neal D
A1 Gunter, Marc J
A1 Jenab, Mazda
A1 Sinha, Rashmi
A1 Keski-Rahkonen, Pekka
A1 Ferrari, Pietro
AB Alcohol is an established risk factor for several cancers, but modest alcohol-cancer associations may be missed because of measurement error in self-reported assessments. Biomarkers of habitual alcohol intake may provide novel insight into the relationship between alcohol and cancer risk. Untargeted metabolomics was used to identify metabolites correlated with self-reported habitual alcohol intake in a discovery dataset from the European Prospective Investigation into Cancer and Nutrition (EPIC; n = 454). Statistically significant correlations were tested in independent datasets of controls from case-control studies nested within EPIC (n = 280) and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC; n = 438) study. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations of alcohol-associated metabolites and self-reported alcohol intake with risk of pancreatic cancer, hepatocellular carcinoma (HCC), liver cancer, and liver disease mortality in the contributing studies. Two metabolites displayed a dose-response association with self-reported alcohol intake: 2-hydroxy-3-methylbutyric acid and an unidentified compound. A 1-SD (log2) increase in levels of 2-hydroxy-3-methylbutyric acid was associated with risk of HCC (OR = 2.54, 95% CI = 1.51 to 4.27) and pancreatic cancer (OR = 1.43, 95% CI = 1.03 to 1.99) in EPIC and liver cancer (OR = 2.00, 95% CI = 1.44 to 2.77) and liver disease mortality (OR = 2.16, 95% CI = 1.63 to 2.86) in ATBC. Conversely, a 1-SD (log2) increase in questionnaire-derived alcohol intake was not associated with HCC or pancreatic cancer in EPIC or liver cancer in ATBC but was associated with liver disease mortality (OR = 2.19, 95% CI = 1.60 to 2.98) in ATBC. 2-hydroxy-3-methylbutyric acid is a candidate biomarker of habitual alcohol intake that may advance the study of alcohol and cancer risk in population-based studies.
YR 2021
FD 2021
LK https://hdl.handle.net/10668/24660
UL https://hdl.handle.net/10668/24660
LA en
DS RISalud
RD Apr 8, 2025